QuiremSpheres® is based on Holmium-166 microspheres, which were developed in the clinic as an alternative to Yttrium-90 microspheres for treating unresectable liver tumors with selective internal radiation therapy (SIRT). Holmium-166 microspheres can be imaged with SPECT and MR, with high sensitivity and resolution, respectively. This makes it possible to perform post-treatment quantitative verification of the achieved dose distribution, i.e. determining dose-to-tumor and dose-to-tissue. With QuiremSpheres® you treat what you see and see what you treat.
QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.
QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.
QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.
QuiremSpheres® is not approved in Canada
1 HEPAR I: Smits et al, 2012 Lancet Oncology
2 HEPAR II: Prince et al, 2017 Journal of Nuclear Medicine